Correlation Between Vaxcyte and Lyra Therapeutics
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Lyra Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Lyra Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Lyra Therapeutics, you can compare the effects of market volatilities on Vaxcyte and Lyra Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Lyra Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Lyra Therapeutics.
Diversification Opportunities for Vaxcyte and Lyra Therapeutics
-0.08 | Correlation Coefficient |
Good diversification
The 3 months correlation between Vaxcyte and Lyra is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Lyra Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyra Therapeutics and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Lyra Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyra Therapeutics has no effect on the direction of Vaxcyte i.e., Vaxcyte and Lyra Therapeutics go up and down completely randomly.
Pair Corralation between Vaxcyte and Lyra Therapeutics
Given the investment horizon of 90 days Vaxcyte is expected to under-perform the Lyra Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vaxcyte is 3.02 times less risky than Lyra Therapeutics. The stock trades about -0.33 of its potential returns per unit of risk. The Lyra Therapeutics is currently generating about -0.1 of returns per unit of risk over similar time horizon. If you would invest 25.00 in Lyra Therapeutics on August 28, 2024 and sell it today you would lose (6.00) from holding Lyra Therapeutics or give up 24.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Vaxcyte vs. Lyra Therapeutics
Performance |
| Timeline |
| Vaxcyte |
| Lyra Therapeutics |
Vaxcyte and Lyra Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vaxcyte and Lyra Therapeutics
The main advantage of trading using opposite Vaxcyte and Lyra Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Lyra Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyra Therapeutics will offset losses from the drop in Lyra Therapeutics' long position.| Vaxcyte vs. Eliem Therapeutics | Vaxcyte vs. HCW Biologics | Vaxcyte vs. Scpharmaceuticals | Vaxcyte vs. Milestone Pharmaceuticals |
| Lyra Therapeutics vs. Eliem Therapeutics | Lyra Therapeutics vs. HCW Biologics | Lyra Therapeutics vs. Scpharmaceuticals | Lyra Therapeutics vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |